文献速递妇科

上皮性卵巢癌中最有效且高效的BRCA1/2检测策略:肿瘤优先还是胚系优先?

The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First?
PubMed 文献 · Gynecol Oncol · 2023-05-12

该研究通过决策分析模型比较肿瘤优先与胚系优先两种BRCA1/2检测策略在上皮性卵巢癌患者中的成本与效果。在真实世界检测接受度下,肿瘤优先策略检测出更多携带胚系BRCA1/2致病性变异的患者及亲属(70% vs 49%),且每例患者和每个家庭的检测成本更低。将实施率设为100%时,肿瘤优先策略每例患者检测成本仍显著更低(€2257 vs €4986)。

要点

  • 肿瘤优先策略在真实世界接受度下可检出70%的胚系BRCA1/2致病性变异,高于胚系优先策略的49%。
  • 肿瘤优先策略每例患者检测成本为€1898,低于胚系优先策略的€2502。
  • 肿瘤优先策略下携带胚系BRCA1/2致病性变异的女性亲属平均多获得0.54个生命年。

核心结论

  • 在上皮性卵巢癌患者中,肿瘤优先策略能以更低的每例患者和每个家庭检测成本更有效地识别胚系BRCA1/2致病性变异。
  • 优化实施肿瘤优先策略可进一步改善卵巢癌患者遗传病因的检出。

研究设计与样本

  • 研究采用决策分析模型比较肿瘤优先策略(以肿瘤DNA检测作为胚系检测的预筛)与胚系优先策略(将所有患者转诊至临床遗传学家进行胚系检测)。
  • 比较基于两种情景:真实世界检测接受度与实施率设为100%。
  • 采用马尔可夫模型分析携带胚系BRCA1/2致病性变异的女性亲属获得的生命年。

主要发现

  • 在真实世界接受度下,肿瘤优先策略检出携带胚系BRCA1/2致病性变异的卵巢癌患者及亲属的比例为70%,胚系优先策略为49%。
  • 肿瘤优先策略每例患者检测成本为€1898,胚系优先策略为€2502;每个家庭检测成本分别为€2511与€2930。
  • 肿瘤优先策略下携带胚系BRCA1/2致病性变异的女性亲属平均多获得0.54个生命年。
  • 在实施率100%情景下,肿瘤优先策略每例卵巢癌患者检测成本为€2257,胚系优先策略为€4986。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Genetic testing in epithelial ovarian cancer (OC) is essential to identify a hereditary cause like a germline BRCA1/2 pathogenic variant (PV). An efficient strategy for genetic testing in OC is highly desired. We evaluated costs and effects of two strategies; (i) Tumor-First strategy, using a tumor DNA test as prescreen to germline testing, and (ii) Germline-First strategy, referring all patients to the clinical geneticist for germline testing. METHODS: Tumor-First and Germline-First were compared in two scenarios; using real-world uptake of testing and setting implementation to 100%. Decision analytic models were built to analyze genetic testing costs (including counseling) per OC patient and per family as well as BRCA1/2 detection probabilities. With a Markov model, the life years gained among female relatives with a germline BRCA1/2 PV was investigated. RESULTS: Focusing on real-world uptake, with the Tumor-First strategy more OC patients and relatives with a germline BRCA1/2 PV are detected (70% versus 49%), at lower genetic testing costs (€1898 versus €2502 per patient, and €2511 versus €2930 per family). Thereby, female relatives with a germline BRCA1/2 PV can live on average 0.54 life years longer with Tumor-First compared to Germline-First. Focusing on 100% uptake, the genetic testing costs per OC patient are substantially lower in the Tumor-First strategy (€2257 versus €4986). CONCLUSIONS: The Tumor-First strategy in OC patients is more effective in identifying germline BRCA1/2 PV at lower genetic testing costs per patient and per family. Optimal implementation of Tumor-First can further improve detection of heredity in OC patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Witjes VM, Ligtenberg MJL, Vos JR, et al. The most efficient and effective BRCA1/2 testing strategy in epithelial ovarian cancer: Tumor-First or Germline-First? Gynecol Oncol. 2023. PMID: 37182432. doi:10.1016/j.ygyno.2023.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。